Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients

被引:79
|
作者
Fujiki, Youhei [1 ]
Kotani, Takuya [1 ]
Isoda, Kentaro [2 ]
Ishida, Takaaki [1 ]
Shoda, Takeshi [2 ]
Yoshida, Shuzo [1 ]
Takeuchi, Tohru [1 ]
Makino, Shigeki [1 ]
机构
[1] Osaka Med Coll, Dept Internal Med 4, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan
[2] Yodogawa Christians Hosp, Dept Rheumatol, Internal Med, Osaka, Japan
关键词
Dermatomyositis; interstitial pneumonia; prognosis; LUNG-DISEASE; AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; POLYMYOSITIS/DERMATOMYOSITIS; COMPLICATION; MYOSITIS; HRCT;
D O I
10.1080/14397595.2017.1318468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We retrospectively investigated clinical prognostic factors for interstitial pneumonia (IP) in anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM) patients. Methods: Subjects comprised 18 patients with anti-MDA5 Ab-positive DM-IP (9 survivors; 9 deaths). Results: Initial serum albumin levels, ferritin levels, and ground-glass opacity (GGO) scores in the right middle lobes were significantly higher in the death group than in the survivor group (p = .033, .013, and .005, respectively). Initial alveolar-arterial oxygen gradient (P[A-a]O-2) was also higher in the death group than in the survivor group (p = .064). Initial serum ferritin, P[A-a]O-2, and right middle lobe GGO score were found to significantly relate to death. Survival rates after 24 weeks were significantly lower among patients with an initial ferritin level of >= 450 ng/mL (25%), P[A-a]O-2 of >= 30 mmHg (31%), and a right middle lobe GGO score of >= 2 (11%) than each of the others (p = .006, .020, and .002, respectively). Conclusions: An initial serum ferritin level of >= 450 ng/mL, P[A-a]O-2 of >= 30 mmHg, and right middle lobe GGO score of >= 2 (GGO >= 5% of the lobe) were identified as poor prognostic factors for anti-MDA5 Ab-positive DM-IP patients.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
  • [21] Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review
    Takanashi, Satoshi
    Kaneko, Yuko
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2022, 32 (01) : 231 - 237
  • [22] Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
    Sakamoto, Noriho
    Ishimoto, Hiroshi
    Nakashima, Shota
    Yura, Hirokazu
    Miyamura, Takuto
    Okuno, Daisuke
    Hara, Atsuko
    Kitazaki, Takeshi
    Kakugawa, Tomoyuki
    Ishimatsu, Yuji
    Satoh, Minoru
    Mukae, Hiroshi
    INTERNAL MEDICINE, 2019, 58 (06) : 837 - 841
  • [23] Clinical Features and Prognostic Factors for Dermatomyositis-Associated Interstitial Lung Diseases with Anti-MDA5 Antibody
    Fujisawa, T.
    Hozumi, H.
    Yasui, H.
    Suzuki, Y.
    Karayama, M.
    Furuhashi, K.
    Enomoto, N.
    Nakamura, Y.
    Inui, N.
    Suda, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [24] Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease
    Ye, Yan
    Fu, Qiong
    Wang, Ran
    Guo, Qiang
    Bao, Chunde
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (08)
  • [25] Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
    Yoshinao Muro
    Kazumitsu Sugiura
    Masashi Akiyama
    Clinical Rheumatology, 2013, 32 : 395 - 398
  • [26] Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
    Muro, Yoshinao
    Sugiura, Kazumitsu
    Akiyama, Masashi
    CLINICAL RHEUMATOLOGY, 2013, 32 (03) : 395 - 398
  • [27] Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine
    Kawamoto, Shinya
    Abe, Toshihiro
    Nagahori, Katsuhiro
    Yoshino, Atsunori
    Fujii, Akiko
    Ono, Yuko
    Ueda, Yoshihiko
    Takeda, Tetsuro
    INTERNAL MEDICINE, 2022, 61 (13) : 2007 - 2012
  • [28] Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis
    Takatani, Ayuko
    Koga, Tomohiro
    Fujita, Yuya
    Fukui, Shoichi
    Endo, Yushiro
    Shimizu, Toshimasa
    Kawakami, Atsushi
    CLINICAL IMMUNOLOGY, 2020, 215
  • [29] Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease
    Fujisawa, Tomoyuki
    Hozumi, Hironao
    Yasui, Hideki
    Suzuki, Yuzo
    Karayama, Masato
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Nakamura, Yutaro
    Inui, Naoki
    Suda, Takafumi
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (08) : 935 - 942
  • [30] Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis
    Kogami, Masahiro
    Abe, Yoshiyuki
    Ando, Taiki
    Makiyama, Ayako
    Yamaji, Ken
    Tamura, Naoto
    RHEUMATOLOGY, 2023, 62 (07) : 2525 - 2533